肝移植术后肝癌复发防治进展

刘召波; 栗光明

doi:10.3969/j.issn.1001-5256.2021.02.006

肝移植术后肝癌复发防治进展

DOI: 10.3969/j.issn.1001-5256.2021.02.006

刘召波,
栗光明^,

首都医科大学附属北京佑安医院普通外科中心，北京 100069

基金项目:

北京医卫健康公益基金会 (LC19003);

北京市医院管理中心重点医学专业发展计划 (ZYLX202124)

作者贡献声明：刘召波负责查阅文献，撰写论文；栗光明负责指导，修改论文及定稿。

详细信息

作者简介:
刘召波(1982—)，男，副主任医师，主要从事肝移植和肝胆疾病研究

通信作者:
栗光明，liguangming@ccmu.edu.cn

中图分类号: R735.7;R617
计量
- 文章访问数: 913
- HTML全文浏览量: 537
- PDF下载量: 101
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-29
- 录用日期: 2020-10-18
- 出版日期: 2021-02-20

Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation

Zhaobo LIU,
Guangming LI^,

Department of General Surgery, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

摘要

摘要: 肝移植是根治性治疗肝癌的方法之一，但肝移植术后肝癌复发严重影响移植患者的长期生存。通过积极的预防措施，免疫抑制剂调整，早期发现以及全面制订肝癌复发后的干预措施，有助于提高肝癌肝移植患者临床疗效并改善长期生存。为了进一步改善肝移植患者预后，从预防复发及复发后的治疗两大方面对肝移植术后肝癌复发的最新防治进展进行归纳和总结。
- 癌, 肝细胞 /
- 肝移植 /
- 复发 /
- 治疗学
Abstract: Liver transplantation is an effective radical treatment method for patients with hepatocellular carcinoma (HCC), but HCC recurrence after liver transplantation seriously affects the long-term survival of patients receiving transplantation. Active preventive measures, adjustment of immunosuppressant, early identification of HCC recurrence, and development of comprehensive intervention measures after recurrence can help to improve the clinical outcome and long-term survival of HCC patients receiving liver transplantation. In order to further improve the prognosis of patients receiving liver transplantation, this article summarizes the latest research advances in the prevention and treatment of HCC recurrence after liver transplantation from the aspects of recurrence prevention and treatment after recurrence.
- Carcinoma, Hepatocellular /
- Liver Transplantation /
- Recurrence /
- Therapeutics

HTML全文

参考文献(45)

[1]	CHAGAS AL, FELGA G, DINIZ MA, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: Clinical profile and prognostic factors of survival[J]. Eur J Gastroenterol Hepatol, 2019, 31(9): 1148-1156. DOI: 10.1097/MEG.0000000000001448
[2]	FOERSTER F, HOPPE-LOTICHIUS M, VOLLMAR J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849. DOI: 10.1177/2050640619840221
[3]	Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008
[4]	AGOPIAN VG, HARLANDER-LOCKE M, ZARRINPAR A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: Analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427. DOI: 10.1016/j.jamcollsurg.2014.12.025
[5]	LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. DOI: 10.3748/wjg.v24.i15.1658
[6]	ORCI LA, BERNEY T, MAJNO PE, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Surg, 2015, 102(10): 1250-1257. DOI: 10.1002/bjs.9868
[7]	NAGAI S, YOSHIDA A, FACCIUTO M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation[J]. Hepatology, 2015, 61(3): 895-904. DOI: 10.1002/hep.27358
[8]	KHALAILEH A, KHOURY T, HARKROSH S, et al. Multiplication product of model for end-stage liver disease and donor risk index as predictive models of survival after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(9): 1116-1120. DOI: 10.1097/MEG.0000000000001396
[9]	LI MR, CHEN GH, CAI CJ, et al. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence[J]. Digestion, 2011, 84(2): 134-141. DOI: 10.1159/000324197
[10]	LAI Q, VITALE A, IESARI S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7): 1023-1033. DOI: 10.1002/lt.25492
[11]	MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4): 493-500. DOI: 10.1001/jamaoncol.2016.5116
[12]	MAZZAFERRO V, SPOSITO C, ZHOU J, et al. Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1): 128-139. DOI: 10.1053/j.gastro.2017.09.025
[13]	BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: Impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/SLA.0000000000001894
[14]	LEE DD, SAPISOCHIN G, MEHTA N, et al. Surveillance for HCC after liver transplantation: Increased monitoring may yield aggressive treatment options and improved post-recurrence survival[J]. Transplantation, 2020. [Epub ahead of print]
[15]	Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese criteria for diagnosis and treatment of primary recurrence after liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 278-280. (in Chinese) 中华医学会器官移植学分会. 中国肝移植术后随访技术规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 278-280.
[16]	LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26. DOI: 10.1002/lt.23566
[17]	FREISE CE, FERRELL L, LIU T, et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma[J]. Transplantation, 1999, 67(4): 510-513. DOI: 10.1097/00007890-199902270-00003
[18]	VIVARELLI M, CUCCHETTI A, PISCAGLIA F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression[J]. Liver Transpl, 2005, 11(5): 497-503. DOI: 10.1002/lt.20391
[19]	RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199. DOI: 10.1016/j.jhep.2013.07.012
[20]	Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese code for immunosuppressive therapy and rejection in liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 262-268. (in Chinese) 中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 262-268.
[21]	CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review[J]. Transpl Int, 2014, 27(10): 1039-1049. DOI: 10.1111/tri.12372
[22]	THORAT A, JENG LB, YANG HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: Re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4): 205-211. DOI: 10.14701/ahbps.2017.21.4.205
[23]	ZHANG ZH, LI LX, LI P, et al. Sirolimus in liver transplant recipients with hepatocellular carcinoma: An updated meta-analysis[J]. J Invest Surg, 2019, 32(7): 632-641. DOI: 10.1080/08941939.2018.1447053
[24]	GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10): 1260-1273. DOI: 10.1111/apt.15253
[25]	GEISSLER EK, SCHNITZBAUER AA, ZVLKE C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125. DOI: 10.1097/TP.0000000000000965
[26]	Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese criteria for diagnosis and treatment of primary recurrence after liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 273-277. (in Chinese) 中华医学会器官移植学分会. 中国肝移植术后原发病复发诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 273-277.
[27]	Committee of Liver Transplantation, Chinese College of Transplant Doctors, Chinese Medical Doctor Association; Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese expert consensus on application of sirolimus in liver transplantation for hepatocellular carcinoma (2020 edition)[J]. J Clin Hepatol, 2020, 36(11): 2429-2434. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.11.007 中国医师协会器官移植医师分会肝移植学组, 中华医学会器官移植学分会肝移植学组. 西罗莫司在肝癌肝移植中应用的中国专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(11): 2429-2434. DOI: 10.3969/j.issn.1001-5256.2020.11.007
[28]	DUAN BW, TIAN LT, LIN DD, et al. Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection[J]. J Viral Hepat, 2019, 26(Suppl 1): 85-89.
[29]	SÖDERDAHL G, BÄCKMAN L, ISONIEMI H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma[J]. Transpl Int, 2006, 19(4): 288-294. DOI: 10.1111/j.1432-2277.2006.00279.x
[30]	BERNAL E, MONTERO JL, DELGADO M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation[J]. Transplant Proc, 2006, 38(8): 2495-2498. DOI: 10.1016/j.transproceed.2006.08.053
[31]	SATAPATHY SK, DAS K, KOCAK M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246. DOI: 10.1111/ctr.13246
[32]	SHETTY K, DASH C, LAURIN J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014, 2014: 913634.
[33]	BERENGUER M, BURRA P, GHOBRIAL M, et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6): 1143-1149. DOI: 10.1097/TP.0000000000003196
[34]	SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6
[35]	FERNANDEZ-SEVILLA E, ALLARD MA, SELTEN J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447. DOI: 10.1002/lt.24742
[36]	KORNBERG A, KVPPER B, TANNAPFEL A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: Clinical patterns and outcome variables[J]. Eur J Surg Oncol, 2010, 36(3): 275-280. DOI: 10.1016/j.ejso.2009.10.001
[37]	YANG Z, WANG S, TIAN XY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 365-370. DOI: 10.1016/j.hbpd.2020.06.002
[38]	AU KP, CHOK K. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45): 5081-5094. DOI: 10.3748/wjg.v24.i45.5081
[39]	INVERNIZZI F, IAVARONE M, CZAUDERNA C, et al. Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: A real-life multicentre study[J]. Digest Liver Dis, 2019, 51(Suppl 1): e12.
[40]	LI H, YANG Z, LI R, et al. Regorafenib combined with sirolimus achieves successful treatment of diffuse double lung metastasis after liver transplantation in giant liver cancer beyond transplantation criteria: A case report[J]. Transplant Proc, 2020, 52(2): 634-637. DOI: 10.1016/j.transproceed.2019.12.001
[41]	ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1
[42]	KUMAR V, SHINAGARE AB, RENNKE HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature[J]. Oncologist, 2020, 25(6): 505-514. DOI: 10.1634/theoncologist.2019-0659
[43]	de BRUYN P, van GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: How far can we go?[J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505
[44]	AGUIRRE LE, GUZMAN ME, LOPES G, et al. Immune checkpoint inhibitors and the risk of allograft rejection: A comprehensive analysis on an emerging issue[J]. Oncologist, 2019, 24(3): 394-401. DOI: 10.1634/theoncologist.2018-0195
[45]	DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05